Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Navidea Biopharmaceuticals, Inc. (NAVB) had Free Cash Flow per Share of $-0.07 for the most recently reported fiscal quarter, ending 2023-09-30.
| Income Statement Financials | |
-- |
|
$-2.26M |
|
-- |
|
-- |
|
$2.13M |
|
$-2.13M |
|
$-0.12M |
|
$-2.26M |
|
$-2.26M |
|
$-2.26M |
|
$-2.26M |
|
$-2.26M |
|
$-2.26M |
|
$-2.13M |
|
$-2.04M |
|
99.36M |
|
99.36M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$4.50M |
|
$0.11M |
|
$1.20M |
|
$5.70M |
|
$7.98M |
|
-- |
|
$0.70M |
|
$8.68M |
|
$-2.98M |
|
$-4.04M |
|
$-2.98M |
|
100.08M |
|
| Cash Flow Statement Financials | |
$-7.28M |
|
$0.63M |
|
$1.10M |
|
$2.00M |
|
$3.86M |
|
$1.87M |
|
$0.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.56 |
|
-- |
|
-- |
|
-- |
|
-0.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
75.68% |
|
55.76% |
|
-39.58% |
|
75.68% |
|
$-0.03 |
|
|
Free Cash Flow per Share |
$-0.07 |
$-0.07 |
|